Intercept’s new PBC liver disease treatment yields successful clinical trials
25 August 2016 | By Intercept Pharmaceuticals
The trial evaluated safety and efficacy of ocaliva in PBC patients with an inadequate therapeutic response to, lack of tolerance to, ursodeoxycholic acid...